E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acute liver failure in paediatric patients |
|
E.1.1.1 | Medical condition in easily understood language |
Infants and children with acute liver failure |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10049844 |
E.1.2 | Term | Acute liver failure |
E.1.2 | System Organ Class | 100000004871 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety, biological activity and tolerability of transplantation of a single dose of microbeads made from the optimum combination of peptide-alginate, mesenchymal stromal cells (MSCs) and hepatocytes to paediatric patients with acute liver failure |
|
E.2.2 | Secondary objectives of the trial |
To establish proof of concept of the transplantation of microbeads made from the optimum combination of peptide-alginate, MSCs and hepatocytes.
To inform sample size and confidence intervals to design a larger randomized clinical trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
I. Infant or child (male or female) under the age of 16 years at recruitment. II. Written informed consent obtained from a parent / legal guardian; III. Presence of ALF defined as a multisystemic disorder in which severe impairment of liver function with or without encephalopathy occurs in association with hepatocellular necrosis reflected as synthetic liver failure in a child with no recognised underlying chronic liver disease. Children must fit one of the ALF categories as described in Appendix 1b; IV. Willing and able to comply with the study visit schedule;
|
|
E.4 | Principal exclusion criteria |
I. Severe ascites causing high intra-abdominal pressure and / or respiratory compromise; II. Intra-abdominal sepsis suspected or proven; III. Clinical condition too unstable to tolerate procedure without compromise; IV. Proven pre-existing allergy or intolerance to alginate on medical history; V. Proven pre-existing allergy to gentamicin on medical history; VI. Intraperitoneal or intra-abdominal malignancy; VII. Adhesions or fistulae to anterior abdominal wall; VIII. Children who weigh in excess of 33kg IX. Pregnant or lactating patients (positive pregnancy test for females of child bearing potential at screening). X. Female patients of childbearing potential who are not willing to use highly effective methods of contraception to prevent pregnancy or abstain from heterosexual activity for the duration of the study. *Females of child bearing potential are females who have experienced menarche and are not surgically sterilised (e.g. by tubal occlusion, hysterectomy, bilateral salpingectomy) or post-menopausal (defined as at least 1 year since last regular menstrual period). ** Highly effective methods of birth control are those with a failure rate of < 1% per year when employed consistently and correctly. Highly effective methods of contraception as per HMA / CTFG working group are combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, the preparation may be oral, intravaginal or transdermal; progesterone-only hormonal contraception associated with inhibition of ovulation which may be oral, injectable or implantable; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomised partner; sexual abstinence through the trial study period; *** Sexual abstinence is considered to be highly effective method only if defined as refraining from heterosexual activity from the date of consent until the week 52 visit. The reliability of this method should be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant. XI. Male patients who are not willing to use an effective method of contraception (condom, vasectomy, sexual abstinence) for the duration of the study, when engaging in sexual activity with a female of childbearing potential; XII. Participation in concurrent therapeutic trial for ALF; XIII. Imminent liver transplantation expected within 12 hours of infusion; XIV. Total hepatectomy; XV. Dependent on Extracorporeal Membrane Oxygenation (ECMO); XVI. Previous liver transplant |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety: Moderate to severe adverse event occurrences due to product in 1st 52 weeks post procedure
Tolerability: assessed by the proportion of initiated infusions where >80% of the infusion is received by the patient.
Biological activity: Survival with native liver at 24 weeks post treatment. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At IMP administration and then at 24 and 52 weeks post treatment |
|
E.5.2 | Secondary end point(s) |
Blood marker levels including haematological, biochemical and coagulation baseline to 52 weeks post treatment. Quality of life measures Survival with native liver at 52 weeks post treatment Survival with transplanted or native liver at 24- and 52-weeks post treatment. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Throughout 52 week trial period |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last patient last 10 year annual follow up post IMP infusion. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |